Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Common Stock, $0.00001 par value per share
-
Shares outstanding
-
28.2M
-
Number of holders
-
105
-
Total 13F shares, excl. options
-
21.1M
-
Shares change
-
+1.17M
-
Total reported value, excl. options
-
$542M
-
Value change
-
+$29.1M
-
Number of buys
-
53
-
Number of sells
-
-38
-
Price
-
$25.71
Significant Holders of LENZ Therapeutics, Inc. - Common Stock, $0.00001 par value per share (LENZ) as of Q1 2025
117 filings reported holding LENZ - LENZ Therapeutics, Inc. - Common Stock, $0.00001 par value per share as of Q1 2025.
LENZ Therapeutics, Inc. - Common Stock, $0.00001 par value per share (LENZ) has 105 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 21.1M shares
of 28.2M outstanding shares and own 74.59% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (4.18M shares), Alpha Wave Global, LP (3.61M shares), Paradigm Biocapital Advisors LP (1.51M shares), VANGUARD GROUP INC (1.2M shares), BlackRock, Inc. (1.17M shares), 72 Investment Holdings, LLC (1.02M shares), SECTORAL ASSET MANAGEMENT INC (977K shares), RTW INVESTMENTS, LP (863K shares), Point72 Asset Management, L.P. (852K shares), and TANG CAPITAL MANAGEMENT LLC (767K shares).
This table shows the top 105 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.